ATS 2019 Virtual Final Program

BASIC • TRANSLATIONAL SCIENTIFIC SYMPOSIUM CME Credits Available: 2 C88 COMPLEMENT AS A NOVEL TARGET TO MITIGATE LUNG DISEASE Assemblies on Respiratory Cell and Molecular Biology; Allergy, Immunology and Inflammation; Pulmonary Infections and Tuberculosis; Thoracic Oncology 2:15 p.m. - 4:15 p.m. KBHCCD Room D220/D227 (Level 2) Target Audience Students, fellows, and basic/translational scientists of all career levels (physician-scientists, PhD scientists) and those focusing on the immunology of lung diseases, such as asthma, COPD, pulmonary fibrosis, lung transplantation and pneumonia Objectives At the conclusion of this session, the participant will be able to: • understand the emerging mechanisms by which key complement proteins modify lung inflammation, with the goal of mitigating diseases such as asthma, pulmonary fibrosis and transplant rejection; • define the relative contribution of complement proteins in driving cell lineage and fate in both immune and non-immune cells, especially stem cells; • critically evaluate cutting-edge technologies being currently used to investigate the role of complement in lung inflammation to be able to broadly apply these to mitigating disease. The complement system has been associated with various lung diseases; however, the extent and the relative contribution from hepatic versus extra-hepatic sources remains ill-defined. Through this session, we will integrate emerging concepts in how complement affects fundamental biological processes, identify model systems and therapies to evaluate how it modulates lung inflammation and answer key questions such as: are complement proteins still predominantly proinflammatory? Do their effects differ in acute lung injury versus chronic lung fibrosis? Chairing: H.S. Kulkarni, MD, MSc, ATSF, Saint Louis, MO R. Vittal, PhD, Ann Arbor, MI J. Kohl, MD, Lubeck, Germany 2:15 Introduction: A New Role for Complement in the Lung - More than Just Pro-Inflammatory Proteins? H.S. Kulkarni, MD, MSc, ATSF, Saint Louis, MO 2:25 Using Complement Regulatory Proteins as Novel Therapeutic Molecules to Combat Pulmonary Fibrosis R. Vittal, PhD, Ann Arbor, MI 2:45 Inhibiting Complement Receptors to Improve Donor Utilization and Outcomes Post-Lung Transplantation C. Atkinson, PhD, Charleston, SC 3:05 Novel Reporter Models as Tools to Delineate the Role of Complement in Pulmonary Tolerance and Allergic Asthma J. Koehl, MD, Lubeck, Germany 3:25 Exploiting Targeted Complement Modulation for Multi-Modal Anticancer Immunotherapies R. Pio, PhD, Pamplona, Spain 3:45 Complement Resistance and Host Susceptibility to MDR K. Pneumoniae Infection J. Lee, MD, ATSF, Pittsburgh, PA 4:05 Panel Discussion (Question and Answers) TRANSLATIONAL SCIENTIFIC SYMPOSIUM CME Credits Available: 2 C89 TRANSLATIONAL DEVELOPMENTS IN TB: TOWARDS IMPROVING PREVENTION AND MANAGEMENT STRATEGIES Assemblies on Pulmonary Infections and Tuberculosis; Allergy, Immunology and Inflammation; Clinical Problems 2:15 p.m. - 4:15 p.m KBHCCD .Ballroom A Three (Level 2) Target Audience Clinicians and physician scientists caring for patients with latent tuberculosis infection (LTBI) and active tuberculosis (TB), and/or working in the field of tuberculosis would benefit the most Objectives At the conclusion of this session, the participant will be able to: • learn new concepts from translational studies and human host defense mechanisms against TB to be better able to diagnose and manage the various forms of TB infections in low and high TB endemic settings; • learn new findings and translational data from TB vaccine research development and trials to be better prepared for future implementation of optimal preventive strategies to improve TB control in low and high TB endemic areas; • learn new diagnostic and therapeutic strategies, including promising technologies to optimally manage patients at risk of TB infection in the U.S. and resource limited settings. This session will present new and emerging data from recent basic and translational studies in TB to update our ATS membership with evolving concepts in TB pathogenesis and novel technologies and strategies for optimal prevention, diagnosis and management of latent TB infection and TB disease. Chairing: P. Escalante, MD, MSc, Rochester, MN J.M. Keane, MD, Dublin, Ireland 2:15 Human Host Responses in TB: Recent Lessons From the Translational World J.M. Keane, MD, Dublin, Ireland 2:35 Evolving Concepts and Interventions in Host Response Against TB: From Host Resistance to Host Tolerance M. Divangahi, PhD, Montreal, Canada 2:55 Enhancing Conventional and Non-Conventional Adaptive Responses in TB: Are We Close to Improve BCG Vaccination Response? D.M. Lewinsohn, MD, PhD, Portland, OR ATS 2019 • Dallas, TX 294 TUESDAY • MAY 21